Exousia Bio (LMMY) Net Cash Flow (2022 - 2025)

Exousia Bio has disclosed Net Cash Flow across 4 years of filings, most recently posting -$1.0 for Q4 2025.

• Net Cash Flow for Q4 2025 came in at -$1.0, changed N/A year-over-year; the trailing twelve-month figure through Nov 2025 was -$1029.0 (changed N/A YoY), and the FY2025 annual result was -$1028.0, up 84.94% from the prior year.
• Net Cash Flow came in at -$1.0 for Q4 2025 at Exousia Bio, up from -$1028.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $3691.0 in Q2 2023 to a low of -$8321.0 in Q3 2022.
• The 4-year median for Net Cash Flow is -$146.0 (2023), against an average of -$1010.8.
• Across the five-year window, Net Cash Flow soared 33.33% in 2023 and plunged 51300.0% in 2025, its largest moves.
• Exousia Bio's Net Cash Flow stood at -$435.0 in 2022, then surged by 33.33% to -$290.0 in 2023, then surged by 100.69% to $2.0 in 2024, then slumped by 150.0% to -$1.0 in 2025.
• The last three Net Cash Flow figures came in at -$1.0 (Q4 2025), -$1028.0 (Q1 2025), and $2.0 (Q2 2024), per Business Quant data.